Literature DB >> 8398265

Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy.

E Protopapa1, G S Delides, L Révész.   

Abstract

Using morphometric analysis of histological preparations, in a retrospective study vascular indices, expressing the extent of vascularisation, were determined for a number of mammary carcinomas. The indices were found to be related to the survival of the patients treated with modified radical mastectomy in combination with pre- and postoperative chemotherapy, the cases with low indices having the shorter survival. The impaired access of the cytotoxic agents to cells in the deficiently vascularised tumours was considered as an explanation. It was concluded that determination of vascular density in tumours may have a prognostic value in regard to the treatment response, and may be helpful in choosing the appropriate treatment.

Entities:  

Mesh:

Year:  1993        PMID: 8398265     DOI: 10.1016/0959-8049(93)90008-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging.

Authors:  S Chawla; S Kim; L A Loevner; W-T Hwang; G Weinstein; A Chalian; H Quon; H Poptani
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-24       Impact factor: 3.825

Review 2.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities.

Authors:  Radu O Minea; Corey M Helchowski; Samuel J Zidovetzki; Fritz K Costa; Stephen D Swenson; Francis S Markland
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

4.  Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients group.

Authors:  Beata Biesaga; Joanna Niemiec; Marek Ziobro
Journal:  Pathol Oncol Res       Date:  2012-05-02       Impact factor: 3.201

5.  Is a histological section representative of whole tumour vascularity in breast cancer?

Authors:  L Martin; C Holcombe; B Green; S J Leinster; J Winstanley
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Role of biological markers in the clinical outcome of colon cancer.

Authors:  O Nanni; A Volpi; G L Frassineti; F De Paola; A M Granato; A Dubini; W Zoli; E Scarpi; D Turci; G Oliverio; A Gambi; D Amadori
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

7.  Development and Validation of a Histological Method to Measure Microvessel Density in Whole-Slide Images of Cancer Tissue.

Authors:  Koen M Marien; Valerie Croons; Yannick Waumans; Ellen Sluydts; Stefanie De Schepper; Luc Andries; Wim Waelput; Erik Fransen; Peter B Vermeulen; Mark M Kockx; Guido R Y De Meyer
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

8.  Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.

Authors:  O Tynninen; J Sjöström; K von Boguslawski; N O Bengtsson; R Heikkilä; P Malmström; B Ostenstad; E Wist; V Valvere; E Saksela; T Paavonen; C Blomqvist
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

9.  The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer.

Authors:  Donald C McMillan; Joanne Edwards; Elizabeth Mallon; Julie C Doughty; Clare Orange; James J Going; Zahra Ma Mohammed
Journal:  BMC Clin Pathol       Date:  2013-11-25

10.  BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy.

Authors:  Beata Biesaga; Joanna Niemiec; Marek Ziobro
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-09       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.